Monday, November 20, 2023 10:55:27 AM
But oh wait, you don't think our pipeline has value or anything to do with the current price increases.
The only things the company has now that it didn't back then is 3x outstanding shares and generic Adderall, which Hakim finagled half ownership. If you want to thank someone for saving the company, thank Jim Huang from SunGen, who got us into Adderall. If he hadn't done that, who knows where we would be.
You choose to ignore Elite's multi-billion dollar pipeline that is a direct results of the tens of millions of dollars invested in R&D. Whatever, but the market sure isn't ignoring that pipeline. No company would ever buy Elite just because it had a generic Adderall ANDA. And it was Nasrat who pulled the SunGen deal out of thin air after the SequestOx failure. It is unlikely that Jim Huang just happened to came knocking at that moment Elite needed it. We all eventually learned that Nasrat had a good hint that the SequestOx submission would probably fail (even if he didn't tell us) before the ANDA was submitted, you posted about this extensively when that became evident and even commented he likely only submitted to get the company its $2 million dollar cash payout for doing so. Elite has also made between at least 2 million of dollars in upgrades to equipment since 2018 that you are conveniently ignoring.
He should have done what CEO's do and gotten off his ass and told this story to people with money to invest and then bought the rights on behalf of the company. Whatever the cost, it would have been less than giving him half of our profits year after year.
SunGen was looking to sell their half fast because they needed the money and would have probably quickly found another buyer if Nasrat hadn't bought it on the spot. You think they would sit around and wait while Nasrat started to make calls (they wouldn't have). We would be much worse off if that money was going to another company. Besides Nasrat only has two things to offer to people who provide money to Elite, interest on a loan, or a pile of shares. If Nasrat had gotten a loan by giving someone a giant pile of shares shares we would also be worse off.
In fact I bought almost all my shares in that range, before I ever heard of Nasrat Hakim and back when there were less than 400 million shares outstanding.
I can't find any price below 0.04 before Nasrat joined but I am only looking at weekly views so a there could have been a few dips under 0.04. Before Nasrat was hired prices of 0.04 only occurred here and there between fall 2010 and spring 2011. So you bought most of your shares 13 years ago when the stock was insanely low and then rode it all the way up to the nearly a dollar and back down without selling most of that investment? Well, ok, but I don't think you should brag about that...
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
